Back to Search Start Over

Synchronous Double Primary Combined Hepatocellular-cholangiocarcinoma and Cholangiolocarcinoma in a Cirrhotic Liver.

Authors :
Sakata M
Kitada K
Omote R
Sonobe H
Utsumi M
Tokunaga N
Fushimi T
Nagao R
Sakata T
Kaneyoshi T
Toyokawa T
Inagaki M
Source :
Journal of clinical and translational hepatology [J Clin Transl Hepatol] 2023 Aug 28; Vol. 11 (4), pp. 991-997. Date of Electronic Publication: 2023 Feb 08.
Publication Year :
2023

Abstract

Both combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and cholangiolocarcinoma are rare primary liver cancers. cHCC-CCA is believed to originate from transformed hepatocellular carcinoma or liver stem/progenitor cells. Cholangiolocarcinoma is characterized by ductular reaction-like anastomosing cords and glands resembling cholangioles or canals containing hepatocellular carcinoma components and adenocarcinoma cells. According to the 2019 revision of the World Health Organization criteria, a subtype with stem cell features as a subclassification of cHCC-CCA was abolished for lack of conclusive evidence of the stem cell origin theory. That led to the classification of cholangiolocarcinoma with hepatocytic differentiation as cHCC-CCA. Consequently, cholangiolocarcinoma without hepatocytic differentiation is classified as a subtype of small-duct cholangiocarcinoma and is assumed to originate from the bile duct. Herein, we report the first case of double primary cHCC-CCA and cholangiolocarcinoma without hepatocytic differentiation in different hepatic segments of a cirrhotic liver. We believe this case supports the validity of the new World Health Organization criteria because the pathological finding of cHCC-CCA in this case shows the transformation of hepatocellular carcinoma to cholangiocarcinoma. Furthermore, this case may demonstrate that immature ductular cell stemness and mature hepatocyte cell stemness in hepatocarcinogenesis can coexist in the same environment. The results provide valuable insights into the mechanisms of growth, differentiation, and regulation of liver cancers.<br />Competing Interests: The authors have no conflict of interests related to this publication.<br /> (© 2023 Authors.)

Details

Language :
English
ISSN :
2310-8819
Volume :
11
Issue :
4
Database :
MEDLINE
Journal :
Journal of clinical and translational hepatology
Publication Type :
Report
Accession number :
37408806
Full Text :
https://doi.org/10.14218/JCTH.2022.00382